Released Mar 20, 2025, after the close
10-K filed Mar 20, 2025, 79 days after period end · 0001390478-25-000003
Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$6.74M-$6.74M derivedN/M vs Q4 2023N/M vs Q3 2024
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$6,918,000N/M
Operating Cash Flowderived-$7,153,000N/M
What the release said
The release
Same quarter
| Metric | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures |
|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $0.00 |
| Net Income | -$6.74M | -$8.14M | -$9.12M | -$6.60M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR